FLAMSA regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
Overview
FLAMSA regimen refers to a regimen consisting of fludarabine, amsacrine, and cytarabine (Ara-C) used as a sequential conditioning therapy for previously untreated patients with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML).[1]
Regimen
Regimen
FLFludarabine
AMSAmsacrine
ACytarabine (Ara-C)
Indications
Indications
- Untreated, high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML)[1]
References
References
- ↑ 1.0 1.1 Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A; et al. (2012). “Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen”. Biol Blood Marrow Transplant. 18 (3): 466–72. doi:10.1016/j.bbmt.2011.09.006. PMID 21963618.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH